Revolutionizing the early detection of Alzheimer's disease through non-invasive biomarkers: the role of artificial intelligence and deep learning

AG Vrahatis, K Skolariki, MG Krokidis, K Lazaros… - Sensors, 2023 - mdpi.com
Alzheimer's disease (AD) is now classified as a silent pandemic due to concerning current
statistics and future predictions. Despite this, no effective treatment or accurate diagnosis …

Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases

A Chudzik, A Śledzianowski, AW Przybyszewski - Sensors, 2024 - mdpi.com
Neurodegenerative diseases (NDs) such as Alzheimer's Disease (AD) and Parkinson's
Disease (PD) are devastating conditions that can develop without noticeable symptoms …

Sex and gender considerations in Alzheimer's disease: The Women's Brain Project contribution

L Castro-Aldrete, MV Moser, G Putignano… - Frontiers in Aging …, 2023 - frontiersin.org
The global population is expected to have about 131.5 million people living with Alzheimer's
disease (AD) and other dementias by 2050, posing a severe health crisis. Dementia is a …

Neurodegenerative disease of the brain: a survey of interdisciplinary approaches

F Davenport, J Gallacher, Z Kourtzi… - Journal of the …, 2023 - royalsocietypublishing.org
Neurodegenerative diseases of the brain pose a major and increasing global health
challenge, with only limited progress made in develo** effective therapies over the last …

The role of patient-reported outcome measures in trials of artificial intelligence health technologies: a systematic evaluation of ClinicalTrials. gov records (1997–2022)

FJ Pearce, SC Rivera, X Liu, E Manna… - The Lancet Digital …, 2023 - thelancet.com
The extent to which patient-reported outcome measures (PROMs) are used in clinical trials
for artificial intelligence (AI) technologies is unknown. In this systematic evaluation, we aim …

Predicting cognitive scores from wearable-based digital physiological features using machine learning: data from a clinical trial in mild cognitive impairment

YG Rykov, MD Patterson, BA Gangwar, SB Jabar… - BMC medicine, 2024 - Springer
Background Continuous assessment and remote monitoring of cognitive function in
individuals with mild cognitive impairment (MCI) enables tracking therapeutic effects and …

Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study

IB Meier, M Buegler, R Harms, A Seixas… - NPJ Digital …, 2021 - nature.com
Conventional neuropsychological assessments for Alzheimer's disease are burdensome
and inaccurate at detecting mild cognitive impairment and predicting Alzheimer's disease …

IoT-driven augmented reality and virtual reality systems in neurological sciences

M Sahu, R Gupta, RK Ambasta, P Kumar - Internet of Things, 2024 - Elsevier
Research in augmented and virtual reality in congregation with the Internet of Things has
opened many avenues in diagnosing and treating neurological disorders. Augmented reality …

Machine learning based algorithms for virtual early detection and screening of neurodegenerative and neurocognitive disorders: a systematic-review

M Yousefi, M Akhbari, Z Mohamadi, S Karami… - Frontiers in …, 2024 - frontiersin.org
Background and aim Neurodegenerative disorders (eg, Alzheimer's, Parkinson's) lead to
neuronal loss; neurocognitive disorders (eg, delirium, dementia) show cognitive decline …

Augmented reality versus standard tests to assess cognition and function in early Alzheimer's disease

M Muurling, C de Boer, S Vairavan, RL Harms… - NPJ digital …, 2023 - nature.com
Augmented reality (AR) apps, in which the virtual and real world are combined, can recreate
instrumental activities of daily living (IADL) and are therefore promising to measure cognition …